Literature DB >> 2846505

Effects of atrial natriuretic polypeptide and organic nitrates on levels of relaxation and cyclic nucleotide of canine coronary artery with and without endothelial injury.

H Nakagawa1, K Okumura, H Hashimoto, T Ito, K Ogawa, T Satake.   

Abstract

We studied the effects of organic nitrates and human atrial natriuretic polypeptide (hANP) on relaxation and tissue cyclic guanosine monophosphate (cGMP) levels using isolated canine coronary arteries with and without endothelial injury. Glyceryl trinitrate (GTN), isosorbide dinitrate (ISDN), pentaerythritol tetranitrate (PETN), and hANP relaxed both the injured and control coronary arteries, and they increased tissue cGMP levels in a dose-dependent fashion without changing tissue adenosine 3':5'-cyclic phosphate (cAMP) levels. The extent of relaxation was larger and the increase in cGMP was greater in the injured coronary artery than in the control artery. Methylene blue inhibited relaxation induced by GTN and hANP, and decreased tissue cGMP levels in both the injured and control groups. M&B 22,948 enhanced relaxation induced by GTN and hANP and increased tissue cGMP levels in both groups. The results suggest that organic nitrates and hANP relax the coronary artery by directly activating the guanylate cyclase in coronary smooth muscle and that such activation is independent of the endothelium-dependent vasodilator system.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2846505     DOI: 10.1007/bf02058683

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  30 in total

1.  Phosphodiesterase inhibitors induce endothelium-dependent relaxation of rat and rabbit aorta by potentiating the effects of spontaneously released endothelium-derived relaxing factor.

Authors:  W Martin; R F Furchgott; G M Villani; D Jothianandan
Journal:  J Pharmacol Exp Ther       Date:  1986-05       Impact factor: 4.030

2.  Atriopeptin II: differential sensitivity of arteries and veins from the rat.

Authors:  M L Cohen; K W Schenck
Journal:  Eur J Pharmacol       Date:  1985-01-15       Impact factor: 4.432

Review 3.  Endothelium-dependent and nitrovasodilator-induced relaxation of vascular smooth muscle: role of cyclic GMP.

Authors:  R M Rapoport; F Murad
Journal:  J Cyclic Nucleotide Protein Phosphor Res       Date:  1983

Review 4.  Role of endothelium in responses of vascular smooth muscle.

Authors:  R F Furchgott
Journal:  Circ Res       Date:  1983-11       Impact factor: 17.367

5.  Morphology after transluminal angioplasty in human beings.

Authors:  P C Block; R K Myler; S Stertzer; J T Fallon
Journal:  N Engl J Med       Date:  1981-08-13       Impact factor: 91.245

6.  Evidence for cyclic GMP-mediated relaxant effects of nitro-compounds in coronary smooth muscle.

Authors:  W R Kukovetz; S Holzmann; A Wurm; G Pöch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-12       Impact factor: 3.000

7.  Correlation between vascular smooth muscle relaxation and increase in cyclic GMP induced by some organic nitro esters.

Authors:  K L Axelsson; R G Andersson; J E Wikberg
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1981-10

8.  Atrial natriuretic factor selectively activates particulate guanylate cyclase and elevates cyclic GMP in rat tissues.

Authors:  S A Waldman; R M Rapoport; F Murad
Journal:  J Biol Chem       Date:  1984-12-10       Impact factor: 5.157

9.  Relationship between cyclic guanosine 3':5'-monophosphate formation and relaxation of coronary arterial smooth muscle by glyceryl trinitrate, nitroprusside, nitrite and nitric oxide: effects of methylene blue and methemoglobin.

Authors:  C A Gruetter; D Y Gruetter; J E Lyon; P J Kadowitz; L J Ignarro
Journal:  J Pharmacol Exp Ther       Date:  1981-10       Impact factor: 4.030

10.  Effects of atrial natriuretic factor, sodium nitroprusside, and acetylcholine on cyclic GMP levels and relaxation in rat aorta.

Authors:  R M Rapoport; S A Waldman; K Schwartz; R J Winquist; F Murad
Journal:  Eur J Pharmacol       Date:  1985-09-24       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.